Kidney involvement in idiopathic multicentric Castleman disease–TAFRO syndrome: clinical spectrum, pathology and outcomes Authors: Shuo Zhang, Hanshu Liu, Siyuan Li, Yubing Wen, Wenling Ye, Wei Ye, Hua Zheng, Lubin Xu, Fei Teng, Ying Wang, Ke Zheng, Peng Xia, Lu Zhang, Jian Li, Xuemei Li, Limeng Chen Published: 2026 ABSTRACT ABSTRACTBackgroundIdiopathic multicentric Castleman disease–thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly syndrome (iMCD-TAFRO) is a clinically aggressive subtype. Renal involvement and its impact on prognosis are poorly characterized. We aimed to describe renal clinicopathological features and outcomes in a large iMCD-TAFRO cohort.MethodsThis 10-year retrospective cohort study enrolled iMCD-TAFRO patients at Peking Union Medical College Hospital. Renal involvement was defined by iMCD consensus criteria. Survival was analyzed using Kaplan–Meier methods.ResultsA total of 48 patients (70.8% male; mean age 45 ± 15 years) were included. Renal involvement was observed in 95.8% (46/48) of the patients, presenting predominantly with reduced urine output, mild hematuria and proteinuria, as well as elevated serum creatinine. Acute kidney injury (AKI) occurred in 80.4% (37/46) of patients showing renal involvement and 37.8% of them required renal replacement therapy. Renal biopsies (n = 7) revealed glomerular microangiopathy in six cases. AKI was associated with elevated C-reactive protein (CRP) and D-dimer levels, and CRP levels correlated with peak serum creatinine levels. Therapy targeting the iMCD was mainly bortezomib, cyclophosphamide and dexamethasone regimen (31/48, 64.6%) with/without anti-interleukin-6 therapy. Nine patients died within hospital or during follow-up. Among AKI patients, 28/37 (75.7%) showed full recovery of renal function. Despite worse renal function at baseline, no significant survival difference was observed between dialyzed and non-dialyzed patients.ConclusionsRenal involvement in iMCD-TAFRO is common and frequently manifests as AKI associated with systemic inflammation. Early and aggressive therapy combined with supportive renal care, including timely dialysis, improved renal recovery and overall prognosis.Keywords: dialysis, idiopathic multicentric Castleman disease, prognosis, renal injury, TAFRO subtype What was known: Idiopathic multicentric Castleman disease–TAFRO syndrome (iMCD-TAFRO) is a rare aggressive subtype with frequent renal involvement; Idiopathic multicentric Castleman disease–TAFRO syndrome (iMCD-TAFRO) is a rare aggressive subtype with frequent renal involvement; Kidney biopsy findings in TAFRO syndrome have been described as membranoproliferative glomerulonephritis–like changes or thrombotic microangiopathy–like changes Kidney biopsy findings in TAFRO syndrome have been described as membranoproliferative glomerulonephritis–like changes or thrombotic microangiopathy–like changes This study adds: In 48 patients with iMCD-TAFRO, renal involvement was nearly universal (95.8%), with acute kidney injury (AKI) in 80.4% [37.8% required renal replacement therapy (RRT)]; biopsy predominantly showed glomerular microangiopathy, and AKI correlated with C-reactive protein. In 48 patients with iMCD-TAFRO, renal involvement was nearly universal (95.8%), with acute kidney injury (AKI) in 80.4% [37.8% required renal replacement therapy (RRT)]; biopsy predominantly showed glomerular microangiopathy, and AKI correlated with C-reactive protein. With bortezomib–cyclophosphamide–dexamethasone (BCD)-based therapy, 75.7% of AKI patients recovered renal function; dialysis did not affect survival. With bortezomib–cyclophosphamide–dexamethasone (BCD)-based therapy, 75.7% of AKI patients recovered renal function; dialysis did not affect survival. Potential impact: Early aggressive therapy and timely RRT may improve renal outcomes; BCD is an effective option, especially where anti-interleukin-6 is unavailable. Early aggressive therapy and timely RRT may improve renal outcomes; BCD is an effective option, especially where anti-interleukin-6 is unavailable. Findings support refined management strategies for renal involvement in iMCD-TAFRO. Findings support refined management strategies for renal involvement in iMCD-TAFRO. INTRODUCTION Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by systemic inflammation and multi-organ involvement [1, 2]. Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly (TAFRO) syndrome, a rare subtype of iMCD, which is defined by thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction and organomegaly, has gained increasing recognition due to its aggressive clinical course and high mortality [3–5]. Renal involvement is a hallmark feature of iMCD-TAFRO and often presents with acute kidney injury (AKI), mild hematuria and low levels of proteinuria, significantly contributing to disease severity. Limited reports showed that renal biopsy typically revealed membranoproliferative glomerulonephritis (MPGN)-like changes or thrombotic microangiopathy (TMA)-like changes [6–8]. Management of AKI in iMCD-TAFRO is challenging due to the lack of standardized treatment protocols. Although anti-inflammatory treatment combined with anti-interleukin-6 (anti-IL-6) treatment have shown promising results, supportive renal care including renal replacement therapy (RRT) are still often required for severe cases. However, due to the scarcity of patients, the clinicopathological characteristics of renal involvement in iMCD-TAFRO, the outcome of AKI and its impact on subsequent prognosis have not been well described in a large cohort before. This study aims to comprehensively characterize the clinical features, pathological findings and prognosis of renal involvements in a large single-center cohort of iMCD-TAFRO patients. By focusing on renal manifestations and their relationship with systemic inflammation and therapeutic interventions, we seek to enhance understanding of this critical complication and inform improved clinical management strategies. MATERIALS AND METHODS Study design and participants This is a single-center retrospective cohort study evaluated hospitalized patients diagnosed with iMCD-TAFRO at Peking Union Medical College Hospital (PUMCH) from January 2015 to December 2024. iMCD-TAFRO was diagnosed following the consensus proposed by the International Castleman’s Disease Collaborative Network diagnostic criteria and iMCD-TAFRO diagnostic criteria in 2021 [9, 10]. Patients with infection-related disorders, autoimmune/autoinflammatory diseases or malignancies that might mimic iMCD were excluded. The study was approved by the Ethics Committee of PUMCH. The informed consents were waived due to the retrospective nature of this study. Definition Renal involvement of iMCD-TAFRO was defined according to minor criteria of iMCD diagnosis criteria: renal dysfunction (estimated glomerular filtration rate <60 mL/min/1.73 m2) or proteinuria (total protein 150 mg/24 h or 10 mg/100 mL) [9]. Biochemical complete remission and partial remission were defined according to the consensus of the diagnosis and treatment of Castleman disease in China [12]. AKI and staging were followed by the Kidney Disease Outcomes Quality Initiative (KDIGO) criteria [13]. End-stage renal disease was defined as irreversible kidney failure with a glomerular filtration rate <15 mL/min/1.73 m² requiring dialysis or conservative management for at least 90 days. Oliguria is defined as a 24-h urine volume of <400 mL. Data collection and pathological diagnosis Data of demographic information, laboratory results, treatment regimens and patient outcomes were collected. All biomarkers [vascular endothelial growth factor (VEGF), IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, high-sensitivity C-reactive protein (hsCRP), D-dimer] were collected at baseline, prior to initiation of disease-targeted therapy [bortezomib–cyclophosphamide–dexamethasone (BCD), anti-IL-6 agents, high-dose corticosteroids]. The standardized definitions of kidney pathological lesions were consistent with recommendations from a working group of the Renal Pathology Society [14]. Pathological diagnoses were all reviewed and confirmed by at least two experienced pathologists. All the renal biopsy specimens underwent complete pathological assessment: light microscopy (including hematoxylin and eosin stain, periodic acid–Schiff stain, periodic acid–silver methenamine stain, Masson trichrome stain), full immunofluorescence panel [immunoglobulin G (IgG), IgA, IgM, complement 3 (C3), C1q, κ/λ light chains] and transmission electron microscopy (EM). Tubular atrophy and interstitial fibrosis were evaluated using the Banff lesion score i-IFTA system. Lesions were scored from 0 to 3, with corresponding percentages of the cortical area affected: 0 for less than 10%, 1 for 10%–25%, 2 for 26%–50% and 3 for more than 50% [15]. Renal arteriolar sclerosing changes such as hyalinization and intimal fibroelastosis were also described. Follow-ups and outcomes Patients were followed in the outpatient clinic at PUMCH or through telephone. Treatment regimens and renal function were documented and treatment responses were evaluated through follow-up. Patients who did not return to PUMCH after discharge and could not be contacted by telephone were defined as lost to follow-up. The follow-up period extended until death, or 31 May 2025. Patients who were discharged against medical advice due to poor prognosis and could not be reached by telephone were considered as dead. Statistical analysis Dichotomous and polychotomous data were compared using the chi-square or Fisher’s exact test. Continuous variables were expressed as the mean ± SD or the median and interquartile range (IQR) according to their distribution. Continuous baseline data were compared using Student’s t-test, the Mann–Whitney U-test and one-way analysis of variance analysis. Survival analysis was conducted using the Kaplan–Meier method. Analyses were performed using the Statistical Package for the Social Sciences (SPSS, version 26.0, SPSS Inc., Chicago, IL, USA), R software (Version 4.5.1; R Foundation for Statistical Computing, Vienna, Austria) and the GraphPad Prism 9 (Version 9.01, GraphPad Software Inc., CA, USA). A P-value of <.05 was considered statistically significant. RESULTS Clinical characteristics of iMCD-TAFRO patients A total of 48 patients with iMCD-TAFRO were included in this study (Fig. 1). The mean age was 45 ± 15 years, and 34 patients were male (70.8%). All patients presented with serous effusion, lymphadenopathy and thrombocytopenia, and nearly all (95.8%) had renal involvement. The median serum VEGF level was 484 (IQR 210–2064) pg/mL (n = 37). Patient flow. A total of 48 patients with iMCD-TAFRO admitted to Peking Union Medical College Hospital from January 2015 to December 2024 were enrolled, with renal involvement in 46 patients. A total of 37 developed AKI, and 37.8% of the AKI patients were treated with dialysis. Renal involvements in iMCD-TAFRO were characterized by AKI and systemic inflammation Renal involvement most commonly presented as AKI (80.4%), accompanied by reduced urine output, hematuria and mild proteinuria (Table 1, Supplementary data, Table S1). Among patients with AKI, 37.8% required renal replacement therapy. Oliguric patients exhibited more severe thrombocytopenia, lower serum albumin, and significantly higher inflammatory markers (hsCRP, D-dimer, IL-10) and peak creatinine compared with non-oliguric patients, and had a higher proportion of myelofibrosis on bone marrow biopsy (Supplementary data, Table S2). Renal biopsy reveals glomerular microangiopathy in iMCD-TAFRO All seven patients underwent ultrasound-guided renal biopsy with unified biopsy indications: persistent unexplained AKI (KDIGO stage 2–3) lasting >7 days. Some of the indicated patients did not received biopsy because of severe uncorrectable thrombocytopenia or refractory shock. Light microscopic studies showed that six cases presented as typical glomerular microangiopathy (GMA), with the specific manifestations exhibiting glomerular endothelial cell swelling, mesangial hypercellularity, as well as expanded subendothelial space (Fig. 2). The average number of glomeruli is 23 ± 12. The ratio of global glomerulosclerosis varied from 0% to 17.6%. Two cases showed acute tubular injury (No. 1 and No. 2), otherwise only mild chronic interstitial tubular damage was observed. Vascular hyalinization and intimal fibrosis were rarely observed. Immunofluorescence studies were negative in these five cases. Patient No. 3 showed weak granular IgA deposition (± to +) in the mesangial regions and capillary loops. Under EM, findings were consistent with GMA, showing endothelial cell swelling and hyperplasia, mesangial cell proliferation and expanded subendothelial space, with no electron-dense deposits observed. Patient No. 5 showed mild-to-moderate mesangial cell proliferation, focal endocapillary hypercellularity, with several cellular crescents (4 of 14 glomeruli) and focal necrotizing lesions of capillary loops. The immunofluorescence studies showed diffuse, granular deposition of IgA++, C3++, kappa light chains (±) and lambda light chains (+) in the mesangial areas. Electron-dense deposits in the mesangial areas and the subendothelial space were also observed under EM. All these changes were consistent with IgA nephropathy, suggesting a co-existed condition with TAFRO. EM studies showed that six cases presented as typical GMA, and one case (Patient No. 5) was consistent with mesangioproliferative glomerulonephritis; endocapillary proliferative glomerulonephritis cannot be excluded. Detailed pathologic descriptions were presented in Table 2. Renal pathology of iMCD-TAFRO. The patients with iMCD-TAFRO usually exhibited GMA in renal pathology, showing endothelial cell swelling (yellow arrow) and proliferation (red arrows), mesangial hypercellularity (green arrow) as well as expanded subendothelial space (blue arrows). (a) periodic acid–Schiff stain, 200×; (b) periodic acid–silver methenamine stain, 200×; (c) EM, 3000×; (d) EM, 4000 × . Table 2:Renal histological characteristics of iMCD-TAFRO patients.No.Age (years)GenderPrimary diseaseHistological changes under light microscopeIFEMGlomerular changesNumber of glomeruliGlobal glomerulosclerosis (n, %)ATIBanff score of tubulointerstitial injuryaVascular lesionsbType, position145MiMCD-TAFROGMA180 (0%)+0+−GMA237MiMCD-TAFROGMA71 (14.3%)+0−−GMA350MiMCD-TAFROGMA173 (17.6%)−1+IgA ± to + in the mesangial areasGMA419FiMCD-TAFROGMA290 (0%)−0−−GMA527MiMCD-TAFROIgAN140 (0%)−0+IgA++, C3++, κ±, λ+, in the mesangial areasMePGN, EnPGN not excluded620MiMCD-TAFROGMA411 (2.4%)−0−GMA745MiMCD-TAFROGMA321 (3.1%)−0+GMA aTubular atrophy and interstitial fibrosis in the injured area were evaluated referring to Banff lesion score i-IFTA system. These lesions were scored 0, 1, 2 and 3, corresponding to <10%, 10%–25%, 26%–50% and >50% of cortical area affected, bVascular lesion indicates hyalinization and intimal fibroelastosis. IgAN, IgA nephropathy; ATI, acute tubular injury; IF, immunofluorescence; MePGN, mesangioproliferative glomerulonephritis; EnPGN, endocapillary proliferative glomerulonephritis; M, male; F, female. Renal histological characteristics of iMCD-TAFRO patients. aTubular atrophy and interstitial fibrosis in the injured area were evaluated referring to Banff lesion score i-IFTA system. These lesions were scored 0, 1, 2 and 3, corresponding to <10%, 10%–25%, 26%–50% and >50% of cortical area affected, bVascular lesion indicates hyalinization and intimal fibroelastosis. IgAN, IgA nephropathy; ATI, acute tubular injury; IF, immunofluorescence; MePGN, mesangioproliferative glomerulonephritis; EnPGN, endocapillary proliferative glomerulonephritis; M, male; F, female. AKI patients showed more severe systemic inflammation than non-AKI patients The patients with AKI (n = 37) were 75.7% male with a mean of 45 ± 15 years. Stage 1, 2 and 3 AKI was seen in 13, 8 and 16 cases, respectively. Fourteen (37.8%) of AKI patients received dialysis. Compared with non-AKI patients, the AKI patients showed more severe systemic disease manifestation and predominant inflammatory statues, such as higher hsCRP and D-dimer levels (Fig. 3, Table 1). The peak serum creatinine (sCr) was correlated with the level of hsCRP (r = 0.520, P < .001) (Fig. 4). None of the serum VEGF nor cytokines (IL-6, IL-8, IL-10 and TNF-α) exhibited a statistically significant correlation with peak sCr by either Pearson or Spearman testing (all P > .05). AKI patients among those with renal involvement showed higher inflammatory markers and worse renal function. In the elevated creatinine patients, AKI patients had worse renal function (a, b) (higher peak creatinine, peak urea) and higher inflammatory markers (c–f) [including white blood cell count (WBC), neutrophils (NEUT), hsCRP and D-dimer]. *P < .05, **P < .01, ***P < .001, ****P < .0001. Table 1:Baseline characteristics of all TAFRO patients, and AKI patients among those with elevated sCr.All (n = 48)Renal involvement (n = 46)AKI (n = 37)Non-AKI (n = 9) P-valueaMale, n (%)34 (70.8)33 (71.7)28 (75.7)5 (55.6).246Age (years)45 ± 1545 ± 1545 ± 1547 ± 15.688SBP (mmHg)125 ± 19126 ± 19125 ± 20131 ± 16.444DBP (mmHg)82 (72, 91)83 (73, 91)83 (71, 92)84 (79, 97).413HR (bpm)93 ± 1493 ± 1493 ± 1594 ± 11.808 Symptoms, n (%) Fever41 (85.4)39 (84.8)32 (86.5)7 (77.8).609 Increased weight19 (39.6)17 (37)14 (37.8)3 (33.3)>.999 Thrombocytopenia48 (100)46 (100)37 (100)9 (100) Serous effusion48 (100)46 (100)37 (100)9 (100) Myelofibrosis16 (33.3)14 (30.4)13 (35.1)1 (11.1).240 Organomegaly48 (100)46 (100)37 (100)9 (100) Decreased urine output40 (83.3)39 (84.8)33 (89.2)6 (66.7).124Immunology, n (%) ANA14 (29.2)13 (28.3)10 (27)3 (33.3).698Laboratory tests White blood cell counts (×109/L)7.62 (4.96, 10.48)7.62 (5.09, 10.84)9.29 ± 4.085.50 ± 2.08.001 Neutrophil counts (×109/L)5.55 (3.50, 8.84)5.55 (3.61, 9.04)6.84 (4.28, 9.54)3.45 (2.37, 3.87).001 Lymphocyte counts (×109/L)1.41 (1.05, 1.82)1.41 (1.02, 1.81)1.43 (1.01, 1.77)1.39 (0.83, 1.99)>.999 Hemoglobin (g/L)97 ± 2397 ± 2398 ± 2591 ± 16.394 Platelet counts (×109/L)b39 (15, 57)36 (13, 58)35 (13, 55)54 (14, 68).513 Alanine aminotransferase (U/L)11 (6, 15)11 (6, 15)11 (6, 15)13 (6, 22).429 Aspartate aminotransferase (U/L)17 (11, 21)17 (12, 22)17 (12, 21)17 (12, 26).828 Albumin (g/L)31 ± 531 ± 531 ± 533 ± 3.169 Total bilirubin (μmol/L)12.5 (8.8, 15.5)12.8 (8.5, 16.4)12.4 (7.7, 17.2)13.1 (10.4 19.4).531 Direct bilirubin (μmol/L)5.4 (3.8, 10.5)5.5 (3.8, 11.1)5.4 (3.7, 11.5)5.7 (4.2, 10.0).849 Gamma-glutamyl transpeptidase (U/L)52 (31, 108)52 (31, 114)53 (32, 131)51 (18, 87).531 Alkaline phosphatase (U/L)138 (85, 228)138 (86, 230)130 (89, 237)138 (82, 205).786 Lactate dehydrogenase (U/L)177 (148, 234)171 (146, 234)166 (144, 222)220 (151, 257).311 K (mmol/L)4.5 ± 0.74.5 ± 0.74.6 ± 0.74.3 ± 0.3.083 Na (mmol/L)137 ± 4137 ± 4137 ± 4138 ± 5.533 Cl (mmol/L)106 ± 5106 ± 5106 ± 5104 ± 6.501 Total CO2 (mmol/L)22.5 (18.6, 26.7)22.5 (18.5, 26.8)21.9 (17.9, 26.4)26.1 (23.3, 28.1).042 Calcium (mmol/L)2.09 ± 0.132.10 ± 0.132.10 ± 0.142.09 ± 0.10.842 Phosphate (mmol/L)1.54 (1.23, 1.96)1.55 (1.24, 1.99)1.68 (1.29, 2.03)1.29 (0.97, 1.48).012 Uric acid (μmol/L)560 (342, 758)560 (353, 760)644 (413, 773)298 (264, 499).007 Peak sCr (μmol/L)193 (143, 331)200 (145, 337)238 (169, 362)105 (53, 135)<.001 Peak urea (mmol/L)24.11 (16.18, 46.33)24.11 (16.18, 45.75)34.96 ± 16.4010.98 ± 5.72<.001 C3 (g/L)0.910 ± 0.2270.918 ± 0.2280.925 ± 0.2410.874 ± 0.124.654 C4 (g/L)0.169 (0.135, 0.245)0.175 (0.142, 0.246)0.175 (0.137, 0.258)0.163 (0.152, 0.212).894 IgG (g/L)14.36 ± 5.3514.59 ± 5.3415.29 ± 5.0511.83 ± 5.85.082 IgA (g/L)1.91 (1.37, 2.72)1.91 (1.38, 2.75)1.89 (1.38, 2.60)2.52 (1.01, 3.16).606 IgM (g/L)0.66 (0.50, 1.05)0.66 (0.51, 1.02)0.67 (0.53, 0.96)0.64 (0.39, 1.17).625 hsCRP (mg/L)78.16 (32.52, 126.43)84.75 (33.41, 127.3)106.08 ± 75.6144.58 ± 38.12.025 Erythrocyte sedimentation rate (mm/h)55 (20, 86)60 (21, 92)62 ± 4153 ± 40.578 IL-6 (pg/mL)11.8 (6.9, 26.0)12.7 (6.9, 26.8)13.1 (7.0, 25.3)7.8 (4.2, 30.3).567 IL-8 (pg/mL)45 (25, 85)46 (23, 85)51 (29, 85)33 (21, 203).758 IL-10 (pg/mL)5.0 (5.0, 9.0)5.0 (5.0, 8.9)5.0 (5.0, 9.0)5.0 (5.0, 6.0).373 TNF-α (pg/mL)17.3 (13.9, 25.6)17.1 (13.7, 25.4)17.1 (14.0, 25.4)16.4 (12.9, 46.4)>.999 D-dimer (mg/L FEU)7.04 (2.97, 13.25)7.37 (2.93, 13.63)9.35 (3.32, 17.20)2.60 (2.03, 5.25).004 NT-proBNP (pg/mL)1561 (625, 2259)1561 (648, 2335)1615 (692, 2958)836 (623, 1708).378 VEGF (pg/mL)484 (210, 2064)495 (225, 2093)740 (210, 2639)286 (257, 484).236 Hematuria, n (%)25 (52.1)25 (54.3)20 (54.1)5 (55.6)>.999 Proteinuria, n (%)34 (70.8)34 (73.9)27 (73)7 (77.8)>.999Therapy, n (%) BCD31 (64.6)27 (58.7)21 (56.8)6 (66.7).716 Anti-IL-6 therapy19 (39.6)17 (37)15 (40.5)2 (22.2).450 Diuretic use38 (79.2)37 (80.4)32 (86.5)5 (55.6).058 Dialysis14 (29.2)14 (30.4)14 (37.8)0 (0)Prognosis Survival time434 (170, 934)434 (165, 940)418 (163, 941)540 (152, 1159).935 Biochemical CR, n (%)33 (68.8)32 (69.6)27 (73.0)5 (55.6).114 Biochemical PR, n (%)2 (4.2)2 (4.3)2 (5.4)0 (0) Death, n (%)9 (18.8)9 (19.6)6 (16.2)3 (33.3).409 Lost to follow-up, n (%)1 (2.1)1 (2.2)1 (2.7)0 (0) Normal creatinine by 3 months, n (%)35 (72.9)34 (73.9)28 (75.7)6 (66.7).666Data are presented as mean ± SD, median (IQR) or n (%). aP-value shows the results between patients with or without AKI. bThe lowest platelet count was collected. SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; ANA, anti-nuclear antibody; NT-proBNP, N-terminal pro brain natriuretic peptide; CR, complete remission; PR, partial remission. Baseline characteristics of all TAFRO patients, and AKI patients among those with elevated sCr. Data are presented as mean ± SD, median (IQR) or n (%). aP-value shows the results between patients with or without AKI. bThe lowest platelet count was collected. SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; ANA, anti-nuclear antibody; NT-proBNP, N-terminal pro brain natriuretic peptide; CR, complete remission; PR, partial remission. The sCr level was correlated with hsCRP. The peak value of sCr is positively correlated with the level of hsCRP. Dialysis-dependent TAFRO patients show higher inflammatory markers Dialysis was most frequently initiated for azotemia, followed by hyperkalemia, volume overload and severe acidosis. Dialyzed patients had lower lymphocyte counts and markedly higher sCR, urea and hsCRP levels (Table 3). The median dialysis duration was 11 (IQR 9, 15) days among those successfully weaned off RRT during hospitalization. Table 3:Clinical characteristics of AKI patients who received dialysis and those who did not receive dialysis.AKI (n = 37)Dialysis (n = 14)Non-dialysis (n = 23) P-valueMale, n (%)28 (75.7)11 (78.6)17 (73.9)>.999Age (years)45 ± 1542 ± 1346 ± 16.452SBP (mmHg)125 ± 20126 ± 18124 ± 21.749DBP (mmHg)83 (71, 92)84 (77, 88)80 (71, 94).632HR (bpm)93 ± 15101 ± 1788 ± 12.010Symptoms, n (%) Fever32 (86.5)14 (100)18 (78.3) Increased weight14 (37.8)5 (35.7)9 (39.1)>.999 Thrombocytopenia37 (100)14 (100)23 (100) Serous effusion37 (100)14 (100)23 (100) Myelofibrosis13 (35.1)7 (50)6 (26.1).171 Organomegaly37 (100)14 (100)23 (100) Decrease urine output33 (89.2)14 (100)19 (82.6)Immunology, n (%) ANA10 (27)2 (14.3)8 (34.8).260Laboratory tests White blood cell counts (×109/L)9.29 ± 4.089.93 ± 4.308.90 ± 4.00.466 Neutrophil counts (×109/L)6.84 (4.28, 9.54)7.97 ± 3.526.55 ± 3.39.231 Lymphocyte counts (×109/L)1.43 (1.01, 1.77)0.99 (0.71, 1.55)1.46 (1.28, 1.82).013 Hemoglobin (g/L)98 ± 2591 ± 21103 ± 26.172 Platelet counts (×109/L)b35 (13, 55)28 ± 2248 ± 33.060 Alanine aminotransferase (U/L)11 (6, 15)11 (7, 18)11 (5, 13).506 Aspartate aminotransferase (U/L)17 (12, 21)20 (11, 32)17 (12, 20).429 Albumin (g/L)31 ± 530 ± 531 ± 5.569 Total bilirubin (μmol/L)12.4 (7.7, 17.2)19.4 (7.3, 24.7)11.1 (7.8, 14.1).077 Direct bilirubin (μmol/L)5.4 (3.7, 11.5)12.9 (3.7, 17.9)5.0 (3.7, 7.3).031 Gamma-glutamyl transpeptidase (U/L)53 (32, 131)50 (37, 148)55 (31, 109).588 Alkaline phosphatase (U/L)130 (89, 237)141 (107, 264)128 (76, 229).411 Lactate dehydrogenase (U/L)166 (144, 222)161 (143, 242)179 (144, 211).699 K (mmol/L)4.6 ± 0.74.7 ± 0.94.5 ± 0.7.364 Na (mmol/L)137 ± 4136 ± 5138 ± 4.175 Cl (mmol/L)106 ± 5104 ± 5107 ± 5.048 Total CO2 (mmol/L)21.9 (17.9, 26.4)19.7 (16.8, 24.6)21.9 (18.7, 26.7).284 Calcium (mmol/L)2.10 ± 0.142.15 (2.02, 2.28)2.12 (1.95, 2.17).130 Phosphate (mmol/L)1.68 (1.29, 2.03)2.23 ± 0.981.54 ± 0.39.023 Uric acid (μmol/L)644 (413, 773)708 ± 304571 ± 206.165 Peak sCr (μmol/L)238 (169, 362)396 (260, 638)188 (158, 288)<.001 Peak urea (mmol/L)34.96 ± 16.4049.43 (44.47, 55.83)22.19 (16.64, 39.90)<.001 C3 (g/L)0.925 ± 0.2411.032 ± 0.2340.866 ± 0.229.065 C4 (g/L)0.175 (0.137, 0.258)0.176 (0.129, 0.307)0.167 (0.138, 0.246).611 IgG (g/L)15.29 ± 5.0516.32 ± 5.3314.70 ± 4.90.362 IgA (g/L)1.89 (1.38, 2.60)2.34 (1.89, 3.16)1.74 (1.14, 2.32).026 IgM (g/L)0.67 (0.53, 0.96)0.70 (0.63, 1.11)0.66 (0.51, 0.86).474 hs-CRP (mg/L)106.08 ± 75.61163.55 ± 74.1171.09 ± 52.22<.001 Erythrocyte sedimentation rate (mm/h)62 ± 4177 ± 4052 ± 40.074 IL-6 (pg/mL)13.1 (7.0, 25.3)10.8 (6.9, 25.3)13.9 (6.9, 26.6).793 IL-8 (pg/mL)51 (29, 85)69 (35, 85)40 (19, 114).292 IL-10 (pg/mL)5.0 (5.0, 9.0)7.3 (5.0, 11.9)5.0 (5.0, 8.0).181 TNF-α (pg/mL)17.1 (14.0, 25.4)16.7 (7.2, 25.6)17.5 (14.6, 25.3).774 D-dimer (mg/L FEU)9.35 (3.32, 17.20)10.29 (5.16, 20.15)9.27 (3.06, 13.25).567 NT-proBNP (pg/mL)1615 (692, 2958)1816 (490, 4880)1260 (755, 2257).552 VEGF (pg/mL)740 (210, 2639)432 (96, 1367)993 (394, 3194).126 Hematuria, n (%)20 (54.1)8 (57.1)12 (52.2).744 Proteinuria, n (%)27 (73)10 (71.4)17 (73.9)>.999Therapy, n (%) BCD21 (56.8)11 (78.6)10 (43.5).048 Anti-IL-6 therapy15 (40.5)9 (64.3)6 (26.1).038 Diuretic use32 (86.5)12 (85.7)20 (87)>.999Prognosis, n (%) Survival time418 (163, 941)368 (172, 581)769 (137, 1589).196 Biochemical CR27 (73.0)9 (64.3)18 (78.3).268 Biochemical PR2 (5.4)2 (14.3)0 (0) Death6 (16.2)2 (14.3)4 (17.4)>.999 Lost to follow-up1 (2.7)0 (0)1 (4.3) Off dialysis12 (32.4)12 (85.7) Normal creatinine by 3 months28 (75.7)10 (71.4)18 (78.3).683Data are presented as mean ± SD, median (IQR) or n (%). aThe lowest PLT count was collected. SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; ANA, anti-nuclear antibody; NT-proBNP, N-terminal pro brain natriuretic peptide; CR, complete remission; PR, partial remission. Clinical characteristics of AKI patients who received dialysis and those who did not receive dialysis. Data are presented as mean ± SD, median (IQR) or n (%). aThe lowest PLT count was collected. SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; ANA, anti-nuclear antibody; NT-proBNP, N-terminal pro brain natriuretic peptide; CR, complete remission; PR, partial remission. Effective therapies achieve high remission in iMCD-TAFRO cohort Therapy targeting the iMCD was mainly BCD (31/48, 64.6%) with/without anti-IL-6 therapy (siltuximab) (Table 1). One death occurred in the hospital. Three patients left the hospital against medical advice due to poor prognosis and they failed to be reached by telephone, thus were presumed dead. One patient was lost to follow-up. For the remaining 43 patients, the median follow-up time was 567 days (IQR 251, 944) by the last follow-up date. During the follow-up, another five patients died. Overall mortality was 19.1% (9/47); septic shock was the most common cause of death (four patients). The biochemical complete and partial remission rates were 74.4% (32/43) and 4.6% (2/43), respectively. Among the AKI patients, 28/37 (75.7%) showed full recovery of renal function during the 3-month follow-up period. No differences with statistical significance in mortality or remission rates were observed between AKI and non-AKI patients. For iMCD-TAFRO patients with AKI, there was no difference in survival between those who were actively dialyzed and those who were not, despite a higher baseline creatinine and urea nitrogen level in dialyzed patients (Fig. 5). Comparisons between survivors and non-survivors revealed no significant differences in baseline VEGF and cytokines (IL-6, IL-8, IL-10 and TNF-α) (all P > .05). Kaplan–Meier survival analysis of iMCD-TAFRO patients. (a) There was no significant difference in survival between hospitalized patients with AKI and those with renal involvement but without AKI. (b) There was no significant difference in survival between patients with AKI and dialysis, and patients with AKI but without dialysis. DISCUSSION This study represents one of the largest single-center cohorts to date focusing on description of renal involvement in iMCD-TAFRO, providing a comprehensive description of clinicopathological features, treatment and outcome. To maximize clinical homogeneity and strengthen the interpretative value of our renal clinicopathological data, we intentionally restricted our study cohort solely to patients who fulfilled the complete diagnostic criteria for iMCD-TAFRO, and excluded isolated TAFRO syndrome cases without confirmed iMCD diagnosis. Our data showed that 80.4% of patients developed AKI and 37.8% of them required RRT. Timely treatment targeting iMCD combined with RRT were helpful for renal recovery. These findings significantly expand current understanding of renal manifestations and their clinical implications in this rare but aggressive disease subtype. Renal involvement was nearly universal in our cohort, and AKI was frequent and often severe, with more than one-third of patients requiring RRT. Despite this apparent severity, renal outcomes were unexpectedly favorable: approximately three-quarters of AKI patients achieved full renal recovery. Clinically, renal involvement in iMCD-TAFRO mainly presented as reduced urine output, mild hematuria and proteinuria, as well as elevated sCr. Renal biopsy findings mainly showed GMA, characterized by endothelial cell swelling, mesangial hypercellularity and expansion of the subendothelial space [6–8, 16]. Notably, typical TMA features such as microthrombi were absent. Chronic damage such as interstitial fibrosis and tubular atrophy was minimal. These pathological features might explain the frequent mismatch observed between the urine output and the level of sCr and the urine output decrease most likely due to capillary leak. Unlike classic proliferative glomerulonephritis or TMA, patients rarely exhibited active urinary sediment or severe hypertension and microangiopathic hemolytic anemia. Meanwhile, AKI in iMCD-TAFRO can be explained by a combination of volume depletion, altered fluid distribution and reduced glomerular filtration rate caused by GMA [6, 7, 16–19]. Fever and the catabolic state associated with the disease may also lead to volume depletion. Hypoalbuminemia and systemic inflammation could promote increased vascular permeability and third-spacing of fluids, leading to intravascular volume depletion despite generalized anasarca, which may precipitate prerenal AKI. These findings align with clinical data and previous reports [7, 16, 19, 20]. The pathogenesis of kidney injury remains unclear in iMCD-TAFRO. The glomerular endothelial cell damage might be the core pathophysiological process based on the clinicopathological features. The elevated inflammatory markers such as IL-6 and VEGF and clinical severity observed in AKI patients suggested the correlation with systemic inflammation with renal injury in iMCD-TAFRO [7]. Spatial and single-cell mapping of iMCD showed that T-zone reticular cells and perivascular reticular cells were the predominant source of increased VEGF expression and IL-6 signaling [21]. Gene expression analysis revealed that the phosphoinositide-3-kinase–protein kinase B (PI3K-Akt) signaling pathway was significantly enriched in the iMCD-TAFRO patients [22]. This pathway, which may be activated by VEGF-A, is known to affect angiogenesis by increasing vascular permeability. A self-reinforcing loop in both lymph nodes and bone marrow, where IL-6 and VEGF fuel each other’s production, leading to sustained inflammatory response was also proposed [23–25]. In the kidney, VEGF is constitutively expressed at high levels in glomerular podocytes and tubular epithelial cells, where it is essential for the maintenance of glomerular endothelial cell fenestrations, survival and normal filtration barrier function [25–27]. In TAFRO syndrome, circulating VEGF is markedly elevated and largely originates from extrarenal sources such as lymph node reticular cells, rather than from local podocyte upregulation [7, 21]. Importantly, a recent immunohistochemical study by Nagayama et al. [16]demonstrated that glomerular VEGF-A staining in podocytes was preserved in TAFRO syndrome without a meaningful difference compared with normal controls, whereas VEGF-A expression in cortical peritubular capillaries was significantly increased [17]. Furthermore, Leurs et al. [19], in their review of 19 iMCD-TAFRO patients who underwent kidney biopsy, proposed that VEGF and IL-6 play a key role in the pathophysiological spectrum of renal involvement from TMA-like lesions to MPGN-like patterns, suggesting the existence of a histopathological continuum driven by these cytokines [20]. Experimental evidence from genetic mouse models reinforces that local VEGF production by podocytes is indispensable for maintaining glomerular endothelial integrity: conditional podocyte-specific deletion of VEGF-A in adult mice results in profound thrombotic glomerular injury, endothelial swelling and proteinuria, closely recapitulating the microangiopathic features observed in VEGF inhibitor–treated patients [27, 28]. Taken together, these converging lines of evidence argue against a negative-feedback mechanism whereby elevated serum VEGF suppresses podocyte-derived VEGF production in TAFRO syndrome. Instead, the glomerular endothelial injury observed in iMCD-TAFRO is more likely driven by the direct effects of excessive circulating VEGF on the glomerular endothelium via PI3K-Akt-mediated signaling, coupled with the synergistic actions of IL-6 and other inflammatory mediators that increase vascular permeability and disrupt endothelial homeostasis [20, 23, 29]. Further mechanistic studies employing kidney tissue-level quantification and longitudinal VEGF monitoring are warranted to elucidate the precise signaling hierarchy in this disease. Our cohort demonstrated that 37.8% of the iMCD-TAFRO patients who suffered from AKI required dialysis, indicating substantial disease severity and organ damage. The primary indications for dialysis were elevated blood urea levels and oliguria refractory to medical management. Compared with studies of AKI due to other causes, dialysis initiation in this cohort appeared to occur at higher blood urea nitrogen levels, suggesting potentially delayed intervention [28]. This may be attributed to intravascular volume depletion, enhanced catabolic state from high-dose glucocorticoid treatment, as well as clinicians’ reluctance to initiate dialysis given severe thrombocytopenia and coagulopathy. In fact, based on our clinical experience, one of the main challenges in managing TAFRO patients is maintaining volume balance and metabolic homeostasis. Nevertheless, prognostic analysis revealed that despite more pronounced inflammatory markers at baseline, patients who underwent dialysis did not have significantly worse outcomes than those who did not after targeted treatment, suggesting that we may need to reconsider the timing and strategy of initiating RRT in this specific population. Based on our data, we recommend that RRT, as supportive care, should be used actively without delay in combination with anti-inflammatory treatment. Given the absence of specified treatment for iMCD-TAFRO, current therapeutic approaches are generally adapted from those used in severe iMCD. In this cohort, treatment with the BCD regimen, with or without IL-6-targeted therapy, yielded favorable biochemical responses, achieving complete or partial remission in the majority of patients. Although IL-6 inhibitors are recommended as first-line therapy for iMCD, their global accessibility is limited: siltuximab has been approved in fewer than 70 countries, and in China it only became commercially available in July 2022, which accounts for its limited use during the earlier period of this two-decade cohort. Moreover, the pivotal phase II trial of siltuximab demonstrated a durable response rate of only 34%, indicating that a substantial proportion of patients may not respond to anti-IL-6 monotherapy [30]. By contrast, the BCD regimen has demonstrated robust efficacy in iMCD [31–33]. A prospective study of BCD in 30 newly diagnosed iMCD patients—including 7 with TAFRO syndrome—reported an overall response rate of 70.0%, with the TAFRO subgroup achieving a particularly favorable response rate of 86.6% [31]. On the basis of this evidence, the Chinese guidelines for Castleman disease have incorporated the BCD regimen as a recommended first-line option [34]. For regions where siltuximab is available, emerging evidence suggests that siltuximab combined with BCD may provide more rapid disease control [33]. Taken together, the BCD regimen represents a rational, evidence-based treatment strategy for iMCD-TAFRO, particularly in settings where IL-6-targeted therapy is inaccessible. Importantly, the presence of AKI or the requirement for dialysis did not portend worse subsequent outcomes, emphasizing the value of early intervention in managing both the systemic disease and renal complications. Unlike many critical care settings where dialysis-requiring AKI is associated with poor outcomes, our data suggest a distinct trajectory in iMCD-TAFRO, in which severe renal dysfunction may still be reversible if the underlying disease is rapidly controlled. RRT should be viewed as an organ-supportive bridge that stabilizes patients during the hyperinflammatory phase and allows time for disease-directed therapy targeting IL-6 and systemic inflammation to take effect. Future therapeutic avenues might explore advanced blood purification techniques aimed at cytokine removal, potentially mitigating inflammation-induced renal injury [35, 36]. Septic shock was the most frequently documented lethal event in our cohort, consistent with a nationwide multicenter Japanese TAFRO registry reporting infection as the primary cause of death and septic shock accounting for nearly all in-hospital fatalities [37]. The sustained intrinsic hypercytokinemia (elevated IL-6 and VEGF) characteristic of iMCD-TAFRO impairs innate and adaptive immune function, predisposing patients to severe infection independent of exogenous immunosuppressive agents [38]. Our decade-long recruitment window spanned a period before siltuximab available in China in July 2022; delayed diagnosis and prolonged uncontrolled systemic inflammation in early cases further amplified infection risks [31]. This study has several limitations. This is a retrospective study conducted in single-center setting, which may limit generalizability. The sample size, although relatively large for this rare disease, remains modest, restricting the statistical power for certain subgroup analyses. Additionally, although we reviewed medical records to identify potential contributing factors for AKI such as sepsis, exposure to nephrotoxic antibiotics and other hemodynamic insults, their influence on the observed AKI severity cannot be fully determined. Three uncontactable discharged patients were statistically presumed dead per study protocol, but their specific lethal etiology could not be captured. Due to the extended time span of this cohort, the treatment protocols varied in different patients. Prospective multicenter studies with larger cohorts are warranted to validate these findings and refine treatment protocols. In conclusion, this study elucidates the clinical and pathological features of iMCD-TAFRO with a focus on renal involvement, highlighting the complex inflammatory and microvascular mechanisms leading to AKI. In iMCD-TAFRO, dialysis-requiring AKI reflects severe but potentially reversible organ dysfunction; therefore, the need for RRT should prompt aggressive supportive care rather than therapeutic nihilism. Supplementary Material Contributor Information Shuo Zhang, Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China. Hanshu Liu, Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China. Siyuan Li, Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. Yubing Wen, Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China. Wenling Ye, Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China. Wei Ye, Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China. Hua Zheng, Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China. Lubin Xu, Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China. Fei Teng, Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China. Ying Wang, Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China. Ke Zheng, Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China. Peng Xia, Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China. Lu Zhang, Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. Jian Li, Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. Xuemei Li, Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China. Limeng Chen, Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on Rare and Complex Urinary System Diseases, Beijing, China. AUTHORS' CONTRIBUTIONS Study design: P.X., L.Z., S.Z. Data collection: S.Z., H.L., S.L., P.X., L.Z., H.Z., L.X., F.T., Y.Wang, K.Z. Data analysis: S.Z., H.L., S.L., P.X., L.Z. Renal pathological image analysis: Y.Wen, Wei Ye, Wenling Ye. Manuscript drafting: S.Z., H.L., S.L., P.X., L.Z. Manuscript review and study supervision: J.L., L.C., X.L. All authors had full access to the data in the study and accept responsibility for the integrity of the data and the accuracy of the data analysis. CONFLICT OF INTEREST STATEMENT The authors declared no conflicts of interest. FUNDING This work was partially supported by grants from the National Key Research and Development Program of China (No. 2023YFC3605500, 2023YFC3605503 to Y.Wenling.), the CAMS Innovation Fund for Medical Sciences (CIFMS 2024-I2M-C&T-B-001 to P.X., 2025-I2M-XHXX-018 to S.Z.), Peking Union Medical College Hospital Talent Cultivation Program (Category C, UBJ11228 to P.X., UBJ10800 to L.Z.; Category D, UHB11957 to S.Z.), National High Level Hospital Clinical Research Funding (2025-PUMCH-C-023 to S.Z.). The funders had no role in the study design, data collection and analysis, decision to publish or manuscript preparation. DATA AVAILABILITY STATEMENT The data underlying this article will be shared upon reasonable request by the corresponding author. REFERENCES Associated Data Supplementary Materials Data Availability Statement The data underlying this article will be shared upon reasonable request by the corresponding author.